1. Home
  2. Supports
  3. Featured Project Solutions
  4. Monkeypox Virus (MPXV) Vaccine Solution

Monkeypox Virus (MPXV) Vaccine Solution

Creative Biolabs offers world-leading monkeypox virus (mpxv) vaccine solutions, utilizing cutting-edge virology and immunology platforms to accelerate your R&D process. We provide one-stop services, covering rational antigen design, vector construction, and comprehensive preclinical testing for various vaccine modalities, including MVA, subunit, and mRNA/DNA vaccines. Partner with us to achieve efficient and safe rapid market entry for novel MPXV vaccines.

Talk to Our Vaccine Experts View Services
Representative image of the Monkeypox Virus (MPXV) vaccine solution.

Core Concepts and Challenges in MPXV Vaccine Solution

The monkeypox virus vaccine solution is a critical strategic tool for combating the spread of zoonotic diseases like monkeypox. MPXV belongs to the orthopoxvirus genus and is closely related to the variola virus (Smallpox). A successful MPXV vaccine must not only induce a potent neutralizing antibody response but also stimulate a long-lasting cellular immune response to provide cross-protection and durable immunity.

Core Concepts and Challenges:

Cross-Protective Immunity

The high homology between MPXV and Variola virus allows for cross-protection using third-generation smallpox vaccines (e.g., ACAM2000, JYNNEOS/Imvamune/Imvanex). However, the next generation of MPXV-specific vaccines must balance safety and immunogenicity.

Safety Profile

Traditional replicating smallpox vaccines can cause severe side effects in immunocompromised populations. Creative Biolabs is dedicated to developing highly attenuated or non-replicating MPXV vaccines to significantly enhance the safety profile.

Rapid Response Mechanism

In the face of an emerging outbreak, rapid vaccine antigen screening, process development, and manufacturing capabilities are crucial for a swift response.

Comprehensive Acceleration of Monkeypox Virus (MPXV) Vaccine R&D

MPXV Rational Antigen Design and High-Throughput Screening

Rational antigen design based on structural biology; gene synthesis and high-efficiency expression of key immunogenic proteins (e.g., A27L, B5R, H3L); high-purity purification and Quality Control (QC) of subunit vaccine proteins.

High-Efficiency Vaccine Vector Customization and Optimization

  • mRNA/DNA Vaccines: Sequence optimization, integration, and optimization of the LNP delivery system.
  • Viral Vector Vaccines: Genetic modification and engineering of poxvirus vectors (MVA, NYVAC) to enhance vaccine expression efficiency.

Preclinical Immunoprotection Efficacy Assessment

  • Humoral Immunity Evaluation: Including PRNT (Plaque Reduction Neutralization Test) and ELISA for antibody titer detection.
  • Cellular Immunity Analysis: ELISpot and ICS for T-cell response detection (e.g., IFN-γ) and cytokine profiling.
  • Animal Model Efficacy Testing: Immunogenicity studies in mice and rabbits, and protective challenge studies in non-human primate (NHP) models following MPXV infection.

Process Development and Production Conversion Support

Detailed Services: Optimization of upstream and downstream process development, consulting for scalability and cost-effectiveness; establishing rigorous Quality Control (QC) methods, stability studies, and preparation of relevant technical documentation.

Reach out to Creative Biolabs for support!

Advanced Monkeypox Virus (MPXV) Vaccine R&D Platforms

Schematic diagram or experimental results of viral vector engineering for MPXV vaccine development.

Advanced Viral Vector Engineering Platform

Focuses on the genetic modification and high-efficiency expression systems of non-replicating poxvirus vectors (such as MVA, NYVAC).

Workflow and technical details of mRNA/LNP rapid construction for MPXV vaccine.

mRNA/LNP Rapid Construction Platform

Achieves rational optimization of mRNA sequences, customized Liposome Nanoparticle (LNP) preparation, and encapsulation to ensure efficient delivery.

Process and screening outcomes of high-throughput immunogenicity testing for MPXV vaccine candidates.

High-Throughput Immunogenicity Screening System

Combines automation technology with bioinformatics analysis to quickly screen the optimal antigen-adjuvant combinations.

Contact us for Detailed Service Items

Efficient Monkeypox Virus (MPXV) Development Process

Antigen Design & Selection

  • Rational design and prediction of key immunogenic T/B cell epitopes based on MPXV and VZV genomic data.

Vector/Delivery System Construction

  • Completing vector gene cloning and optimization based on client needs (DNA, mRNA, subunit, or viral vector).

Lab-Scale Vaccine Preparation

  • Small-scale production of vaccine candidates under P2 laboratory conditions and preliminary purification.

In Vitro Immunoassay

  • Conducting preliminary ELISA and neutralization tests to screen the most promising candidates.

Pre-Clinical Animal Studies

  • Evaluating immunogenicity, safety, and protective efficacy in mouse or NHP models.

Process Development & Optimization

  • Optimizing production process parameters to ensure scalability and cost-effectiveness.
Partner with Creative Biolabs Now!

The Outstanding Edge of Creative Biolabs' MPXV Vaccine Solution

Comprehensive Experience

We possess over a decade of experience in Poxviridae research, with mature technology platforms, especially for MVA and NYVAC vectors.

One-Stop Integrated Services

Provides seamless services from concept to preclinical studies, significantly shortening the MPXV vaccine R&D cycle.

High Safety Design

Focuses on developing non-replicating or highly attenuated vaccines to ensure product safety, especially in immunocompromised populations.

Rapid Response Capability

Equipped with the ability to quickly adjust production lines, allowing for the rapid launch of monkeypox virus (MPXV) vaccine projects in response to emerging public health events.

Summary of the outstanding advantages of Creative Biolabs' MPXV vaccine solution.

Authentic Feedback on Monkeypox Virus (MPXV) Vaccine Solution

"The speed of the MPXV vaccine solutions service provided by Creative Biolabs was highly impressive. Their mRNA LNP platform helped us complete candidate screening and preliminary animal trials within three months, and the data quality exceeded expectations. We are extremely grateful for their expertise and quick turnaround."

- R&D Director

Biotech Company

"Using Creative Biolabs’ MVA vector engineering services, we successfully constructed a high-expression monkeypox virus subunit vaccine. Their expert team not only provided technical support but also offered crucial advice on immunological assessment. The collaboration was excellent, and the results were reliable."

- University Virology Professor

"In our monkeypox virus vaccine project, Creative Biolabs demonstrated outstanding process development capabilities. They helped us resolve several critical bottlenecks in large-scale production, laying a solid foundation for our IND submission."

- Project Manager

Multinational Pharmaceutical Company

Case Study

mRNA Vaccines Targeting MPXV A35R and M1R Antigens

Background

Amid mpox outbreaks and limitations of current vaccines (ACAM2000's safety risks, JYNNEOS' scarcity), this study developed three mRNA vaccines (VGPox 1/2/3) targeting MPXV A35R (EEV antigen) and M1R (IMV antigen) to evaluate their immunogenicity and protection against lethal vaccinia virus (VACV, homologous to MPXV) in mice.

Solution

VGPox 1/2 encode A35R extracellular domain-M1R fusions (with signal peptide); VGPox 3 mixes full-length A35R/M1R mRNAs. Female Balb/c mice got 10μg intramuscular doses (0/14 days for 2-dose; day 0 for 1-dose). Sera/spleens were tested for antibodies (ELISA/PRNT) and T cells (flow cytometry); mice were intranasally challenged with lethal VACV-WR.

Result

All vaccines induced early anti-A35R antibodies; VGPox 1/2 triggered earlier anti-M1R and stronger neutralizing antibodies. Single-dose vaccines protected mice within 7 days; all showed long-term (5-month) protection. VGPox 2 had best passive protection, outperforming live VACV, supporting their potential as MPXV vaccine alternatives.

Experimental data demonstrating the protective effect of mRNA vaccination against MPXV challenge.
Protection of mRNA Vaccination for MPXV Challenge.
Hou, Fujun, et al. "mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge." Nature communications 14.1 (2023): 5925. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41467-023-41628-5.

Frequently Asked Questions about MPXV Vaccine Solution

What main technology platforms are covered by Creative Biolabs' Monkeypox Virus (MPXV) Vaccine Solutions?

We offer comprehensive technology support, primarily including attenuated live viral vectors (e.g., MVA, NYVAC), nucleic acid vaccines (mRNA/DNA), and recombinant subunit vaccines.

How do you ensure the safety of MPXV vaccine candidates?

Safety is our primary concern. We mainly develop non-replicating vectors (like MVA) and use strict vector engineering to ensure they cannot fully replicate in host cells, thereby significantly reducing the risk of side effects.

Roughly how long does it take from antigen design to the preclinical report for an MPXV vaccine?

Given our mature platforms and rapid response mechanism, if all components (such as antigen sequence, vector) are defined, the process from vector construction to the completion of the preliminary preclinical animal immunogenicity report typically takes 4-6 months.

How do you determine the optimal immunization dose and adjuvant selection for an MPXV vaccine?

We provide dose-escalation studies and adjuvant screening services. By combining in vitro immunogenicity analysis and in vivo animal model testing, we can assess antibody titers and T-cell responses at different doses, thus scientifically determining the optimal immunization regimen.

Can your MPXV vaccine services be customized for specific MPXV variants?

Absolutely. Our antigen design platform can perform targeted antigen optimization and epitope customization based on the sequence data of the latest MPXV strains (e.g., Clades I or II), ensuring maximum breadth of protection and efficacy for the vaccine.

Initiate Your MPXV Vaccine Development Consultation

If you are seeking innovative strategies or a reliable partnership to accelerate your MPXV (Monkeypox/Mpox) vaccine project, please contact our dedicated team. We offer cutting-edge research services, comprehensive development platforms, and expert consultation to address the unique challenges of orthopoxvirus vaccine creation.

Contact Us
Online Inquiry

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Project Description:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


(USA)



Vaccine - Creative Biolabs
ISO 9001 Certified - Creative Biolabs Quality Management System
Shopping Basket